IL17A and neoplasm: However, when IL-17A was neutralized using an anti-IL-17A antibody, tumor growth inhibition was significantly reduced in mice receiving LYC-54143-treated cells (Fig. 4F, Type 17 LYC-54143 + IgG vs. Type 17 LYC-54143 + Anti-IL-17A) relative to mice receiving vehicle-treated cells (Fig. 4F, Type 17 + IgG vs. Type 17 + Anti-IL-17A), suggesting that the antitumor efficacy of LYC-54143-treated cells is at least partially dependent on IL-17A in this model.